Trial Profile
A dose-response relationship study of SR141716 [rimonabant] in obese patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Sanofi
- 14 Apr 2009 Actual patient number (527) added as reported by ClinicalTrials.gov.
- 14 Apr 2009 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 19 Apr 2007 New trial record.